These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34806011)

  • 1. Cefiderocol treatment for carbapenem-resistant
    Pascale R; Pasquini Z; Bartoletti M; Caiazzo L; Fornaro G; Bussini L; Volpato F; Marchionni E; Rinaldi M; Trapani F; Temperoni C; Gaibani P; Ambretti S; Barchiesi F; Viale P; Giannella M
    JAC Antimicrob Resist; 2021 Dec; 3(4):dlab174. PubMed ID: 34806011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant
    Mazzitelli M; Gregori D; Sasset L; Trevenzoli M; Scaglione V; Lo Menzo S; Marinello S; Mengato D; Venturini F; Tiberio I; Navalesi P; Cattelan A
    Microorganisms; 2023 Apr; 11(4):. PubMed ID: 37110408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.
    Falcone M; Tiseo G; Leonildi A; Della Sala L; Vecchione A; Barnini S; Farcomeni A; Menichetti F
    Antimicrob Agents Chemother; 2022 May; 66(5):e0214221. PubMed ID: 35311522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study.
    Bavaro DF; Papagni R; Belati A; Diella L; De Luca A; Brindicci G; De Gennaro N; Di Gennaro F; Romanelli F; Stolfa S; Ronga L; Mosca A; Pomarico F; Dell'Aera M; Stufano M; Dalfino L; Grasso S; Saracino A
    Infect Dis Ther; 2023 Aug; 12(8):2147-2163. PubMed ID: 37653122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbapenem-Resistant
    Giannella M; Verardi S; Karas A; Abdel Hadi H; Dupont H; Soriano A; Santerre Henriksen A; Cooper A; Falcone M;
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad329. PubMed ID: 37496600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of First-Line Therapy with Old and Novel Antibiotics in Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant
    Dalfino L; Stufano M; Bavaro DF; Diella L; Belati A; Stolfa S; Romanelli F; Ronga L; Di Mussi R; Murgolo F; Loconsole D; Chironna M; Mosca A; Montagna MT; Saracino A; Grasso S
    Antibiotics (Basel); 2023 Jun; 12(6):. PubMed ID: 37370367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?
    Corcione S; De Benedetto I; Pinna SM; Vita D; Lupia T; Montrucchio G; Brazzi L; De Rosa FG
    J Infect Public Health; 2022 Sep; 15(9):975-979. PubMed ID: 35961239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience.
    Piccica M; Spinicci M; Botta A; Bianco V; Lagi F; Graziani L; Faragona A; Parrella R; Giani T; Bartolini A; Morroni G; Bernardo M; Rossolini GM; Tavio M; Giacometti A; Bartoloni A
    J Antimicrob Chemother; 2023 Nov; 78(11):2752-2761. PubMed ID: 37807834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefiderocol-containing regimens for the treatment of carbapenem-resistant
    Rando E; Cutuli SL; Sangiorgi F; Tanzarella ES; Giovannenze F; De Angelis G; Murri R; Antonelli M; Fantoni M; De Pascale G
    JAC Antimicrob Resist; 2023 Aug; 5(4):dlad085. PubMed ID: 37484029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Burden of Carbapenem-Resistant
    Montrucchio G; Corcione S; Lupia T; Shbaklo N; Olivieri C; Poggioli M; Pagni A; Colombo D; Roasio A; Bosso S; Racca F; Bonato V; Della Corte F; Guido S; Della Selva A; Ravera E; Barzaghi N; Cerrano M; Caironi P; Berta G; Casalini C; Scapino B; Grio M; Parlanti Garbero M; Buono G; Finessi F; Erbetta S; Sciacca PF; Fiore G; Cerutti A; Livigni S; Silengo D; Agostini F; Berardino M; Navarra M; Vendramin S; Castenetto E; Liccardi MM; Manno E; Brazzi L; De Rosa FG
    J Clin Med; 2022 Sep; 11(17):. PubMed ID: 36079137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant
    Campogiani L; Crea AMA; Minardi ML; Ansaldo L; Coppola L; Compagno M; Vitale P; Spalliera I; Malagnino V; Teti E; D'agostini C; Pennacchiotti C; Abate DN; Celeste MG; Andreoni M; Iannetta M; Sarmati L
    Open Forum Infect Dis; 2023 Dec; 10(12):ofad627. PubMed ID: 38156051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis.
    Onorato L; de Luca I; Monari C; Coppola N
    J Infect; 2024 Mar; 88(3):106113. PubMed ID: 38331328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis.
    Gatti M; Cosentino F; Giannella M; Viale P; Pea F
    Int J Antimicrob Agents; 2024 Feb; 63(2):107047. PubMed ID: 38061418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol.
    Gatti M; Bartoletti M; Cojutti PG; Gaibani P; Conti M; Giannella M; Viale P; Pea F
    J Glob Antimicrob Resist; 2021 Dec; 27():294-298. PubMed ID: 34710630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study.
    Giacobbe DR; Labate L; Russo Artimagnella C; Marelli C; Signori A; Di Pilato V; Aldieri C; Bandera A; Briano F; Cacopardo B; Calabresi A; Capra Marzani F; Carretta A; Cattelan A; Ceccarelli L; Cenderello G; Corcione S; Cortegiani A; Cultrera R; De Rosa FG; Del Bono V; Del Puente F; Fanelli C; Fava F; Francisci D; Geremia N; Graziani L; Lombardi A; Losito AR; Maida I; Marino A; Mazzitelli M; Merli M; Monardo R; Mularoni A; Oltolini C; Pallotto C; Pontali E; Raffaelli F; Rinaldi M; Ripa M; Santantonio TA; Serino FS; Spinicci M; Torti C; Trecarichi EM; Tumbarello M; Mikulska M; Giacomini M; Marchese A; Vena A; Bassetti M;
    Infect Dis Ther; 2024 Jul; ():. PubMed ID: 38995601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019.
    Pogue JM; Zhou Y; Kanakamedala H; Cai B
    BMC Infect Dis; 2022 Jan; 22(1):36. PubMed ID: 34991499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
    Jain M; Sharma A; Sen MK; Rani V; Gaind R; Suri JC
    Microb Pathog; 2019 Mar; 128():75-81. PubMed ID: 30562602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii.
    Oliva A; Ceccarelli G; De Angelis M; Sacco F; Miele MC; Mastroianni CM; Venditti M
    J Glob Antimicrob Resist; 2020 Dec; 23():292-296. PubMed ID: 33065329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit.
    Russo A; Gavaruzzi F; Ceccarelli G; Borrazzo C; Oliva A; Alessandri F; Magnanimi E; Pugliese F; Venditti M
    Infection; 2022 Feb; 50(1):83-92. PubMed ID: 34176088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.